Journal article
A phase II study of ZD6474 (Zactima™), a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma—NCIC CTG IND.145
Abstract
Multiple myeloma is a disease in which angiogenesis is postulated to be a target for therapy. Based on this hypothesis, we conducted a phase II trial of ZD6474 (Zactima™; a VEGFR inhibitor) 100 mg p.o. daily in patients with relapsed multiple myeloma. The primary efficacy endpoint was objective response as assessed by reduction in M protein. There were 18 patients with a mean age of 64 years. One patient was ineligible and one was not …
Authors
Kovacs MJ; Reece DE; Marcellus D; Meyer RM; Mathews S; Dong R-P; Eisenhauer E
Journal
Investigational New Drugs, Vol. 24, No. 6, pp. 529–535
Publisher
Springer Nature
Publication Date
November 2006
DOI
10.1007/s10637-006-9022-7
ISSN
0167-6997